This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The global polycythemia vera market is currently in the growth stage of its lifecycle. While polycythemia vera remains a rare disease, the market is experiencing increasing awareness, improved diagnostic capabilities, and advancements in treatment options, particularly with the introduction of targeted therapies such as JAK2 inhibitors and RNA-targeted medicines. These innovations are helping address unmet needs in polycythemia vera management, driving market expansion.
Additionally, regulatory incentives such as orphan drug designation are encouraging more companies to enter the market, further fueling growth. The market is also benefiting from increasing healthcare access in emerging regions and the growing focus on personalized medicine. However, it is still developing in terms of market penetration, especially in less-represented areas, indicating a strong potential for continued growth in the coming years.
Impact
- Increasing demand for polycythemia vera therapies is anticipated to support the growth of the global polycythemia vera market during the forecast period 2025-2035.
- The global polycythemia vera market is expected to grow at a significant rate due to developments in targeted therapies, rising awareness and diagnosis, and a growing clinical pipeline.
Market Segmentation:
Segmentation 1: by Region
- North America
- Europe
- Asia-Pacific
- Rest-of-the-World
North America is expected to dominate the global polycythemia vera market during the forecast period due to its advanced healthcare infrastructure, high prevalence, and increased awareness of the disease. The region also benefits from regulatory advantages and a strong pharmaceutical presence, which accelerates the availability of effective treatments and drives the growth of the global polycythemia vera market.
Recent Developments
- Partnerships: In March 2025, Ionis Pharmaceuticals, Inc. and Ono Pharmaceutical Co., Ltd. announced that they had entered into a license agreement granting Ono exclusive global rights for the development and commercialization of sapablursen, an investigational RNA-targeted medicine for polycythemia vera.
- Regulatory Activities: In March 2025, ANVISA approved BESREMi (ropeginterferon alfa-2b) for the treatment of adult patients with polycythemia vera.
- Regulatory Activities: In January 2025, VGT-1849A, an antisense oligonucleotide-based novel Janus kinase 2 (JAK2) inhibitor, received Orphan Drug Designation from the FDA for the management of polycythemia vera.
Demand - Drivers and Limitations
The following are the drivers for the global polycythemia vera market:
- Increasing Prevalence of Polycythemia Vera
- Rising Awareness and Advancements in Diagnostic Technologies
The global polycythemia vera market is expected to face some limitations too, due to the following challenges:
- High Treatment Costs
How Can This Report Add Value to an Organization?
Product/Innovation Strategy: Innovations in the global polycythemia vera market are centered on advancing treatment options to enhance patient care. Key players in the market, such as Ionis Pharmaceuticals, Inc. and Vanda Pharmaceuticals, have been involved in the development of therapies for polycythemia vera.
Competitive Strategy: Enterprises led by market leaders continually update their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product pipeline and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.
Key Market Players and Competition Synopsis
The companies profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolios, and market penetration.
Some of the prominent names established in this market are:
- Novartis AG
- Merck
- Protagonist Therapeutics, Inc.
- Mabwell Bioscience Co., Ltd.
- Silence Therapeutics plc
- PharmaEssentia
- AOP Orphan Pharmaceuticals AG
- Incyte Corporation
- Ionis Pharmaceuticals, Inc.
- Hoffmann-La Roche
- Vanda Pharmaceuticals
- Ono Pharmaceutical Co., Ltd.
- Takeda
- Pint Pharma
This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.
Table of Contents
Executive Summary
Scope of Study
Companies Mentioned
- Novartis AG
- Merck
- Protagonist Therapeutics, Inc.
- Mabwell Bioscience Co., Ltd.
- Silence Therapeutics plc
- PharmaEssentia
- AOP Orphan Pharmaceuticals AG
- Incyte Corporation
- Ionis Pharmaceuticals, Inc.
- Hoffmann-La Roche
- Vanda Pharmaceuticals
- Ono Pharmaceutical Co., Ltd.
- Takeda
- Pint Pharma
